UNTHSC gets $1.5 million to study possible glaucoma treatment

By Jan Jarvis

Dr Zode in lab

First, Gulab Zode, PhD, and his team of researchers discovered how a gene that causes glaucoma leads to the pathology in the eye. Then they found a drug to treat and cure a rare form of the blinding eye disease.

Now that same drug could one day be used to treat open angle glaucoma, the most common form of the disease.

Previous studies showed that the drug sodium-phenybutyrate plays an important role in reducing the elevated pressure that causes glaucoma, said Dr. Zode, Associate Professor of Pharmacology & Neuroscience.

“What we hope to show is that this drug can be used to not only treat a rare form of glaucoma, but cure all forms of the disease,” Dr. Zode said.

Dr. Zode recently received a $1.5 million grant from National Eye Institute to study how the drug can be used as a targeted treatment for open angle glaucoma. For many years, patients with glaucoma have been treated with drugs that reduce intraocular pressure but the actual cause of the disease has never been addressed.

If this drug proves effective, it could open the door to a cure for the second leading cause of irreversible blindness. The drug has been shown to be effective for the genetic form of the disease that affects about 2 million people under the age of 40 worldwide. But it is now being studied as a treatment for the more than 64 million people in the world who have open angle glaucoma.

In previous studies, researchers at the North Texas Eye Research Institute were able to eliminate myocilin, a protein involved in both juvenile and adult-onset open-angle glaucoma, and lower intraocular pressure to prevent further damage to the eye.

Using the drug sodium 4-phenybutyrate, it is possible to target the ER stress pathway and correct the damage caused by glaucoma, Dr. Zode said.

“None of the treatments so far target the pathology of the disease,” he said. “But this drug can target the pathway that causes the damage to the eye.”

The Food and Drug Administration has already approved the drug for urea cycle disorders, a hereditary metabolic condition caused by a deficiency of one of the enzymes in the urea cycle responsible for removing ammonia from the bloodstream.

“Our goal is to take the studies being done now and take them to a clinic to be tested in patients,” Dr. Zode said.

Recent News

Abe Clark
  • Research
|Mar 28, 2024

Dr. Abe Clark honored with international research award

Abbot “Abe” Clark, PhD, FARVO, FAAO, regents professor of pharmacology and neuroscience in the School of Biomedical Sciences at The University of North Texas Health Science Center at Fort Worth, has received the International Society for Eye Research 2024 Ernst H. Bárány Prize.   The awar...
Processed With Lensa With Pt12 Filter
  • Research
|Mar 28, 2024

Dr. Steven Romero receives American Physiological Society award for excellence in research

Dr. Steven Romero, associate professor of Physiology and Anatomy at the School of Biomedical Sciences at The University of North Texas Health Science Center at Fort Worth, was named the 2024 Henry Pickering Bowditch Award Lecturer by the American Physiological Society. The lectureship is awarded to ...
Screenshot 2024 03 28 At 8.50.12 am
  • Our People
|Mar 28, 2024

Physical therapy student lands prestigious role in national organization

When Jonathan Hansen was an undergraduate intern at Texas Health Arlington Memorial Hospital, he encountered a man who had just suffered a stroke. The patient’s right side was completely paralyzed. Hansen, now a first-year student in The University of North Texas Health Science Center at Fort Wort...
Jackie In Dc
  • Our People
|Mar 27, 2024

Personalized Health and Well-Being student repays generosity through advocacy

In 2019, The University of North Texas Health Science Center at Fort Worth student Jacqueline Green said she felt hopeless. She became pregnant while experiencing hard financial times, and she didn’t have insurance. Compounding her stress was terrible grief. Her mother-in-law suddenly passed away,...